+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 12Years +
All Genders
ID04585750

Assessment of Oral PC14586 Alone or with Pembrolizumab in Patients with Advanced Solid Tumors Carrying TP53 Y220C Mutation

Led by PMV Pharmaceuticals, Inc · Updated on 2026-10-02

300

Participants Needed

76

Research Sites

54 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of PC14586 rezatapopt, an oral drug designed to reactivate the p53 protein specifically for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. This Phase 12 study includes a Phase 1 portion assessing safety, tolerability, and early effects of various doses of rezatapopt alone and combined with pembrolizumab, as well as a Phase 2 portion focusing on the drugs efficacy and safety at the recommended dose in different cancer types. Participants receive daily oral doses of rezatapopt, with dose levels adjusted to find the maximum tolerated dose and recommended Phase 2 dose. Some participants receive rezatapopt alone, while others receive it combined with pembrolizumab given intravenously every three weeks. Expansion groups include patients with different tumor types such as ovarian, lung, breast, and endometrial cancers, all harboring the TP53 Y220C mutation. The study monitors participants over several months to evaluate response rates and safety. Throughout the study, participants undergo regular assessments including imaging to measure tumor response according to RECIST criteria, blood tests to study drug levels and safety, and quality of life questionnaires. Safety is closely monitored by tracking adverse events. The total study duration varies but includes extended follow-up of up to 34 months in Phase 2. The trial is non-randomized and open-label, allowing researchers to gather detailed information on the drugs effects in this patient population.

CONDITIONS

Brief Title

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Research Team

P

PMV Pharma Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here